Tetsuya Murata
Tetsuya Murata has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Taizo Shiraishi
4 shared publicationsKenji Tanigawa
3 shared publications- Masatoshi Watanabe
Department of Oncologic Pathology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu 514-8507, Mie, Japan
3 shared publications - Hiroyoshi Suzuki
Department of Urology, Chiba University Graduate School of Medicine
2 shared publications Ken-Ichiro Hoshino
Department of Internal Medicine, JA Suzuka Hospital, Japan
2 shared publicationsMasami Kato
Department of Internal Medicine, JA Suzuka Hospital, Japan
2 shared publications
Latest Publications
- 5 February 2009
- Vol. 28, 3711-6
Lack of involvement of the GNAS1 T393C polymorphism in prostate cancer risk in a Japanese population.
GNAS1 encodes the a-subunit of the Gs protein (Gsa), which binds GTP and stimulates adenylyl cyclase. Activating mutations lead to somatotroph, thyroid, adrenal and gonadal adenomas or the McCune-Albright syndrome and recently the T399C polymorphism in GNAS1 has been reported to be associated with malignancies. The purpose of the present case-control study with 349 Japanese prostate cancer patients and 203 urological controls was to determine whether the GNAS1 T393C polymorphism is associated with prostate cancer risk. The GNAS1 T393C polymorphism was examined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Odds ratios (OR) were adjusted for age using multiple logistic regression analysis with SPSS Medical Pack. The allele frequencies were compatible with the control population in Hardy-Weinberg equilibrium with 80, 169 and 100 for GNAS1 C/C, C/T and T/T, respectively in the patients with prostate cancer, compared with 42, 94 and 67 in the controls. No association between the GNAS1 polymorphism and prostate cancer risk was apparent. The C/C genotype was more frequent among the prostate cancer patients (22.9%) than the controls (20.7%), although without significance (OR, 1.30; 95% CI, 0.80-2.12; p=0.29). This pilot study does not support involvement of the GNAS1 polymorphism in prostate cancer risk.
- 5 February 2009
- Vol. 28, 3711-6
Lack of involvement of the GNAS1 T393C polymorphism in prostate cancer risk in a Japanese population.
GNAS1 encodes the a-subunit of the Gs protein (Gsa), which binds GTP and stimulates adenylyl cyclase. Activating mutations lead to somatotroph, thyroid, adrenal and gonadal adenomas or the McCune-Albright syndrome and recently the T399C polymorphism in GNAS1 has been reported to be associated with malignancies. The purpose of the present case-control study with 349 Japanese prostate cancer patients and 203 urological controls was to determine whether the GNAS1 T393C polymorphism is associated with prostate cancer risk. The GNAS1 T393C polymorphism was examined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Odds ratios (OR) were adjusted for age using multiple logistic regression analysis with SPSS Medical Pack. The allele frequencies were compatible with the control population in Hardy-Weinberg equilibrium with 80, 169 and 100 for GNAS1 C/C, C/T and T/T, respectively in the patients with prostate cancer, compared with 42, 94 and 67 in the controls. No association between the GNAS1 polymorphism and prostate cancer risk was apparent. The C/C genotype was more frequent among the prostate cancer patients (22.9%) than the controls (20.7%), although without significance (OR, 1.30; 95% CI, 0.80-2.12; p=0.29). This pilot study does not support involvement of the GNAS1 polymorphism in prostate cancer risk.
- 1 September 2004
- Vol. 31 (9) , 1365-70
[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].
The use of neoadjuvant chemotherapy for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors, especially for patients with Stage IV b (Japan criteria). We report our experience with a six-drug chemotherapeutic regimen that resulted in sufficient downstaging of the tumor in some patients to justify surgical resection. From Jan. 2001 through December 2003, 6 patients received 5-FU as a continuous infusion (200 mg/m2/day), calcium leucovorin weekly by intravenous bolus injection (30 mg/m2), mitomycin-C every 6 weeks (10 mg/m2 intravenously), and dipyridamole daily orally (75 mg), according to the UCLA regimen and gemcitabine weekly (600 mg/m2) and heparin as a continuous infusion (0-3,000 U/day) for locally advanced unresected pancreatic cancer. All of these patients were evaluable for response and survival. There were 5 partial responses (83% response rate) and 1 no response. Four of 5 responding patients had sufficient tumor regression to meet clinical criteria for resectability, three of whom underwent a curative resection. All patients who underwent downstage operation were still alive for the follow-up period (4-23 months).
- 1 September 2004
- Vol. 31 (9) , 1365-70
[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].
The use of neoadjuvant chemotherapy for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors, especially for patients with Stage IV b (Japan criteria). We report our experience with a six-drug chemotherapeutic regimen that resulted in sufficient downstaging of the tumor in some patients to justify surgical resection. From Jan. 2001 through December 2003, 6 patients received 5-FU as a continuous infusion (200 mg/m2/day), calcium leucovorin weekly by intravenous bolus injection (30 mg/m2), mitomycin-C every 6 weeks (10 mg/m2 intravenously), and dipyridamole daily orally (75 mg), according to the UCLA regimen and gemcitabine weekly (600 mg/m2) and heparin as a continuous infusion (0-3,000 U/day) for locally advanced unresected pancreatic cancer. All of these patients were evaluable for response and survival. There were 5 partial responses (83% response rate) and 1 no response. Four of 5 responding patients had sufficient tumor regression to meet clinical criteria for resectability, three of whom underwent a curative resection. All patients who underwent downstage operation were still alive for the follow-up period (4-23 months).
- 28 August 2004
- Vol. 24 (4) , 2431-7
Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population.
Carcinogenesis of the prostate involves androgen influences, and associations between genetic polymorphisms of androgen receptor and metabolizing enzymes and prostate cancer risk have been reported. Roles for non-androgenic hormones are not well defined, but they also may have an impact judging from epidemiological and animal experimental alphalambda zeta of data. The purpose of the study was to determine whether hormone-related polymorphisms are associated with prostate cancer risk. A case-control study was performed with 147 Japanese prostate cancer patients and 266 urological controls. Polymorphisms of target genes [cytochrome P450 (CYP) 1B1, Leu432Val; debrisoquine hydroxylase, (CYP2D6)*4; aromatase (CYP19), Arg264Cys; estrogen receptor (ER)alpha-Xx (Xba I) and Pp (Pvu II); ERbeta-Rr (Rsa I); progesterone receptor (PR) Alu in intron 7] were examined by PCR-based methods. The capital and small letters signify the absence and presence of restriction sites, respectively. Odds ratios (OR) were adjusted for age using multiple logistic regression analysis with SPSS Medical Pack. Among the seven examined genetic polymorphisms, significant associations between CYP1B1 Leu432Val (OR 4.80; 95% confidence interval (CI), 1.21-19.05) and Alu in intron 7 of PR (OR 4.17; 95%CI, 1.26-13.85) were found. As for combined effects, the CYP1B1 polymorphisms (Leu/Val+Val/Val) together with heterozygosity for Alu in the PR were more frequent among prostate cancer patients (1.45%) than controls (0.41%), although without significance (OR, 3.99; 95%CI, 0.36-44.8). The combination of ERalpha (P/p+p/p) polymorphisms with heterozygosity for Alu in the PR demonstrated an OR of 4.56 (95%CI, 1.01-20.6). This pilot study showed that CYP1B1 and PR polymorphisms, alone or in combination, might be associated with prostate cancer risk. They might, therefore, have potential as a tool for identifying high-risk individuals.
- 28 August 2004
- Vol. 24 (4) , 2431-7
Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population.
Carcinogenesis of the prostate involves androgen influences, and associations between genetic polymorphisms of androgen receptor and metabolizing enzymes and prostate cancer risk have been reported. Roles for non-androgenic hormones are not well defined, but they also may have an impact judging from epidemiological and animal experimental alphalambda zeta of data. The purpose of the study was to determine whether hormone-related polymorphisms are associated with prostate cancer risk. A case-control study was performed with 147 Japanese prostate cancer patients and 266 urological controls. Polymorphisms of target genes [cytochrome P450 (CYP) 1B1, Leu432Val; debrisoquine hydroxylase, (CYP2D6)*4; aromatase (CYP19), Arg264Cys; estrogen receptor (ER)alpha-Xx (Xba I) and Pp (Pvu II); ERbeta-Rr (Rsa I); progesterone receptor (PR) Alu in intron 7] were examined by PCR-based methods. The capital and small letters signify the absence and presence of restriction sites, respectively. Odds ratios (OR) were adjusted for age using multiple logistic regression analysis with SPSS Medical Pack. Among the seven examined genetic polymorphisms, significant associations between CYP1B1 Leu432Val (OR 4.80; 95% confidence interval (CI), 1.21-19.05) and Alu in intron 7 of PR (OR 4.17; 95%CI, 1.26-13.85) were found. As for combined effects, the CYP1B1 polymorphisms (Leu/Val+Val/Val) together with heterozygosity for Alu in the PR were more frequent among prostate cancer patients (1.45%) than controls (0.41%), although without significance (OR, 3.99; 95%CI, 0.36-44.8). The combination of ERalpha (P/p+p/p) polymorphisms with heterozygosity for Alu in the PR demonstrated an OR of 4.56 (95%CI, 1.01-20.6). This pilot study showed that CYP1B1 and PR polymorphisms, alone or in combination, might be associated with prostate cancer risk. They might, therefore, have potential as a tool for identifying high-risk individuals.
- 1 July 2002
- Published by Wiley in Pathology International
- Vol. 52 (7) , 488-491
Esophageal anthracosis: Lesion mimicking malignant melanoma
- 1 July 2002
- Published by Wiley in Pathology International
- Vol. 52 (7) , 488-491
Esophageal anthracosis: Lesion mimicking malignant melanoma
- 1 January 2001
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 62 (3) , 781-785
Successfully resected carcinosarcoma of the middle portion of the bile duct. Report of a case.
- 1 January 2001
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 62 (3) , 781-785
Successfully resected carcinosarcoma of the middle portion of the bile duct. Report of a case.
- 1 January 2000
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 39 (11) , 914-919
Gastrointestinal Stromal Tumors of the Small Intestine That Expressed c-kit Protein.
We report two patients with gastrointestinal stromal tumors (GISTs) of the small intestine that expressed c-kit protein (CD117). One was a 68-year-old woman with epigastralgia and vomiting. A submucosal tumor of the upper jejunum was detected, and partial resection was carried out. The histology revealed a GIST negative for CD34 but positive for CD117. The other was a 42-year-old woman with progressive anemia, melena and lower abdominal pain. Intussusception was detected, and a partial resection was carried out. A submucosal tumor of the lower jejunum was noted. The histology revealed a GIST positive for both CD34 and CD117.
- 1 January 2000
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 39 (11) , 914-919
Gastrointestinal Stromal Tumors of the Small Intestine That Expressed c-kit Protein.
We report two patients with gastrointestinal stromal tumors (GISTs) of the small intestine that expressed c-kit protein (CD117). One was a 68-year-old woman with epigastralgia and vomiting. A submucosal tumor of the upper jejunum was detected, and partial resection was carried out. The histology revealed a GIST negative for CD34 but positive for CD117. The other was a 42-year-old woman with progressive anemia, melena and lower abdominal pain. Intussusception was detected, and a partial resection was carried out. A submucosal tumor of the lower jejunum was noted. The histology revealed a GIST positive for both CD34 and CD117.
- 1 January 1999
- Published by The Japanese Society of Clinical Cytology in The Journal of the Japanese Society of Clinical Cytology
- Vol. 38 (1) , 115-116
A case of salivary duct carcinoma of the parotic gland.
Cytologic findings of salivary duct carcinoma (SDC) of the parotic gland obtained by fine needle aspiration are described. The aspirates contained predominantly broad flat sheets and surrounding isolated cells. These were large polygonal epithelial cells with abundant eosinophilic cytoplasm, round to oval nuclei, fine granular chromatin and predominant nucleoli. Though some cells revealed intracytoplasmic lumen on histologic sections, this was inconspicuous cytologically.The cytologic differential diagnosis included mucoepidermoid carcinoma, oncocytic carcinoma, acinic cell carcinoma, and metastatic carcinoma. The presence of ICL has only been described in one article that demonstrated it electronmicroscopically.
- 1 January 1999
- Published by The Japanese Society of Clinical Cytology in The Journal of the Japanese Society of Clinical Cytology
- Vol. 38 (1) , 115-116
A case of salivary duct carcinoma of the parotic gland.
Cytologic findings of salivary duct carcinoma (SDC) of the parotic gland obtained by fine needle aspiration are described. The aspirates contained predominantly broad flat sheets and surrounding isolated cells. These were large polygonal epithelial cells with abundant eosinophilic cytoplasm, round to oval nuclei, fine granular chromatin and predominant nucleoli. Though some cells revealed intracytoplasmic lumen on histologic sections, this was inconspicuous cytologically.The cytologic differential diagnosis included mucoepidermoid carcinoma, oncocytic carcinoma, acinic cell carcinoma, and metastatic carcinoma. The presence of ICL has only been described in one article that demonstrated it electronmicroscopically.